SELLAS Life Sciences (SLS) R&D In Process (2022)
SELLAS Life Sciences (SLS) reported R&D In Process of $10.0 million for Q1 2022.
SELLAS Life Sciences (SLS) has 1 years of R&D In Process data on file, last reported at $10.0 million in Q1 2022.
- Quarterly R&D In Process changed N/A year-over-year to $10.0 million in Q1 2022, while the trailing twelve-month figure through Dec 2022 was $10.0 million (changed N/A YoY) and the FY2022 annual result came in at $10.0 million, changed N/A from the prior year.
- R&D In Process was little changed at $10.0 million in Q1 2022 per SLS's latest filing.
- Across five years, R&D In Process topped out at $10.0 million in Q1 2022 and bottomed at $10.0 million in Q1 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D In Process (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 500,000.00 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 101.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 10.00 Mn |